These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9062472)

  • 1. Growth hormone--ready for prime time?
    Marcus R; Reaven GM
    J Clin Endocrinol Metab; 1997 Mar; 82(3):725-6. PubMed ID: 9062472
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of growth hormone administration in human obesity.
    Shadid S; Jensen MD
    Obes Res; 2003 Feb; 11(2):170-5. PubMed ID: 12582210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial.
    Franco C; Brandberg J; Lönn L; Andersson B; Bengtsson BA; Johannsson G
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1466-74. PubMed ID: 15598680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience.
    Hwu CM; Kwok CF; Lai TY; Shih KC; Lee TS; Hsiao LC; Lee SH; Fang VS; Ho LT
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3285-92. PubMed ID: 9329355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome.
    Wajchenberg BL
    Endocr Rev; 2000 Dec; 21(6):697-738. PubMed ID: 11133069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance in visceral obesity.
    Kissebah AH
    Int J Obes; 1991 Sep; 15 Suppl 2():109-15. PubMed ID: 1794931
    [No Abstract]   [Full Text] [Related]  

  • 7. [Visceral adipose tissue and metabolic syndrome].
    Blüher M; Paschke R
    Dtsch Med Wochenschr; 2003 Oct; 128(44):2319-23. PubMed ID: 14593576
    [No Abstract]   [Full Text] [Related]  

  • 8. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
    Mogul HR; Lee PD; Whitman BY; Zipf WB; Frey M; Myers S; Cahan M; Pinyerd B; Southren AL
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in body composition and fat distribution in growth hormone-deficient prepubertal children during growth hormone therapy.
    Roemmich JN; Huerta MG; Sundaresan SM; Rogol AD
    Metabolism; 2001 May; 50(5):537-47. PubMed ID: 11319714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral adipose tissue is associated with circulating high affinity growth hormone-binding protein.
    Roelen CA; Koppeschaar HP; de Vries WR; Snel YE; Doerga ME; Zelissen PM; Thijssen JH; Blankenstein MA
    J Clin Endocrinol Metab; 1997 Mar; 82(3):760-4. PubMed ID: 9062478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity.
    Albert SG; Mooradian AD
    J Clin Endocrinol Metab; 2004 Feb; 89(2):695-701. PubMed ID: 14764783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body composition during GH treatment in Prader-Labhardt-Willi syndrome.
    Bosio L; Beccaria L; Benzi F; Sanzari A; Chiumello G
    J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():351-3. PubMed ID: 10698601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
    Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance.
    Weyer C; Foley JE; Bogardus C; Tataranni PA; Pratley RE
    Diabetologia; 2000 Dec; 43(12):1498-506. PubMed ID: 11151758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone research and therapy.
    Grunfield C; Papadakis M
    Science; 1997 Jan; 275(5299):465. PubMed ID: 9019805
    [No Abstract]   [Full Text] [Related]  

  • 17. [Metabolic difference between visceral fat and subcutaneous abdominal fat].
    Björntorp P
    Diabetes Metab; 2000 Jun; 26 Suppl 3():10-2. PubMed ID: 10945144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
    Ahn CW; Kim CS; Nam JH; Kim HJ; Nam JS; Park JS; Kang ES; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):444-9. PubMed ID: 16584518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Insulin resistance syndrome, visceral fat syndrome].
    Nakamura T; Matsuzawa Y
    Nihon Rinsho; 1997 Nov; 55 Suppl():792-8. PubMed ID: 9434566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.